[1] |
Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down⁃regulates multiple proinflammatory pathways in psoriasis plaques[J]. J Immunol, 2005, 175(4): 2721⁃2729. DOI: 10.4049/jimmunol.175.4.2721.
|
[2] |
Kimber I, Cumberbatch M, Dearman RJ, et al. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization[J]. Br J Dermatol, 2000, 142(3): 401⁃412. DOI: 10.1046/j.1365⁃2133.2000.03349.x.
|
[3] |
Langley RG, Strober BE, Gu Y, et al. Benefit⁃risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis[J]. Br J Dermatol, 2010, 162(6): 1349⁃1358. DOI: 10.1111/j.1365⁃2133.2010.09707.x.
|
[4] |
Ahmad K, Rogers S. Three years′ experience with infliximab in recalcitrant psoriasis[J]. Clin Exp Dermatol, 2006, 31(5): 630⁃633. DOI: 10.1111/j.1365⁃2230.2006.02170.x.
|
[5] |
Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre[J]. Br J Dermatol, 2009, 160(1): 162⁃169. DOI: 10.1111/j.1365⁃2133.2008.08865.x.
|
[6] |
余晓玲, 晋红中. 英夫利西单抗治疗关节病性银屑病进展[J]. 中华皮肤科杂志, 2014, 47(3): 223⁃225. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.03.023.
|
|
Yu XL, Jin HZ. Infliximab for the treatment of psoriatic arthropathica: an update[J]. Chin J Dermatol, 2014, 47(3): 223⁃225. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.03.023.
|
[7] |
Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate⁃to⁃severe plaque psoriasis[J]. J Am Acad Dermatol, 2007, 56(1): 31. DOI: 10.1016/j.jaad.2006.07.017.
|
[8] |
张堂德, 李琳琳, 罗妙璇. 英夫利西单抗治疗寻常性银屑病七例[J]. 中华皮肤科杂志, 2015, 48(6): 438⁃439. DOI: 10.3760/cma.j.issn.0412⁃4030.2015.06.024.
|
|
Zhang DT, Li LL, Luo MX. Infliximab for the treatment of seven patients with psoriasis vulgaris[J]. Chin J Dermatol, 2015, 48(6): 438⁃439. DOI: 10.3760/cma.j.issn.0412⁃4030.2015.06.024.
|
[9] |
Fabroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients[J]. J Eur Acad Dermatol Venereol, 2011, 25(5): 549⁃553. DOI: 10.1111/j.1468⁃3083.2010.03826.x.
|
[10] |
Gómez⁃Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection[J]. Arthritis Rheum, 2007, 57(5): 756⁃761. DOI: 10.1002/art.22768.
|